[1]	SEQUENCE FROM NUCLEIC ACID. MEDLINE=85230577; PubMed=4006916; [NCBI, ExPASy, EBI, Israel, Japan] Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; "Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells."; EMBO J. 4:1251-1255(1985).
[2]	SEQUENCE FROM NUCLEIC ACID. MEDLINE=87064416; PubMed=2946935; [NCBI, ExPASy, EBI, Israel, Japan] Lamb P., Crawford L.; "Characterization of the human p53 gene."; Mol. Cell. Biol. 6:1379-1385(1986).
[3]	SEQUENCE FROM NUCLEIC ACID. MEDLINE=85267676; PubMed=3894933; [NCBI, ExPASy, EBI, Israel, Japan] Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; "Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53."; Mol. Cell. Biol. 5:1601-1610(1985).
[4]	SEQUENCE FROM NUCLEIC ACID. MEDLINE=87089826; PubMed=3025664; [NCBI, ExPASy, EBI, Israel, Japan] Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; "Molecular basis for heterogeneity of the human p53 protein."; Mol. Cell. Biol. 6:4650-4656(1986).
[5]	SEQUENCE FROM NUCLEIC ACID. MEDLINE=89108008; PubMed=2905688; [NCBI, ExPASy, EBI, Israel, Japan] Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; "A variation in the structure of the protein-coding region of the human p53 gene."; Gene 70:245-252(1988).
[6]	SEQUENCE OF 101-393 FROM NUCLEIC ACID. MEDLINE=85126934; PubMed=6396087; [NCBI, ExPASy, EBI, Israel, Japan] Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; "Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene."; EMBO J. 3:3257-3262(1984).
[7]	SEQUENCE FROM NUCLEIC ACID. MEDLINE=92007731; PubMed=1915267; [NCBI, ExPASy, EBI, Israel, Japan] Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; "p53 is frequently mutated in Burkitt's lymphoma cell lines."; EMBO J. 10:2879-2887(1991).
[8]	SEQUENCE FROM NUCLEIC ACID. Chumakov P.M., Almazov V.P., Jenkins J.R.; Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
[9]	SEQUENCE FROM NUCLEIC ACID. Rozemuller E.H., Tilanus M.G.J.; "P53 genomic sequence. Corrections and polymorphism."; Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
[10]	SEQUENCE FROM NUCLEIC ACID. Anderson C.W., Kieleczawa J., Allalunis-Turner J.; "Human p53 from the malignant glioma-derived cell lines M059J and M059K have a cancer-associated mutation in exon 8."; Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
[11]	ALTERNATIVE SPLICING. MEDLINE=96197761; PubMed=8632903; [NCBI, ExPASy, EBI, Israel, Japan] Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., Gilbert D., Iggo R., Frebourg T.; "The human tumour suppressor gene p53 is alternatively spliced in normal cells."; Oncogene 12:813-818(1996).
[12]	NUCLEAR LOCALIZATION SIGNAL. MEDLINE=90191730; PubMed=2156209; [NCBI, ExPASy, EBI, Israel, Japan] Addison C., Jenkins J.R., Sturzbecher H.-W.; "The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif."; Oncogene 5:423-426(1990).
[13]	MINIMAL REPRESSION DOMAIN. PubMed=11007800; [NCBI, EBI] Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; "p53 amino acids 339-346 represent the minimal p53 repression domain."; J. Biol. Chem. 276:1510-1515(2001).
[14]	PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. MEDLINE=90280456; PubMed=2141171; [NCBI, ExPASy, EBI, Israel, Japan] Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
[15]	DEPHOSPHORYLATION BY PP2A. MEDLINE=91172186; PubMed=1848668; [NCBI, ExPASy, EBI, Israel, Japan] Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen."; Mol. Cell. Biol. 11:1996-2003(1991).
[16]	O-GLYCOSYLATION. MEDLINE=96197773; PubMed=8632915; [NCBI, ExPASy, EBI, Israel, Japan] Shaw P., Freeman J., Bovey R., Iggo R.; "Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus."; Oncogene 12:921-930(1996).
[17]	PHOSPHORYLATION BY PRPK. MEDLINE=21570176; PubMed=11546806; [NCBI, ExPASy, EBI, Israel, Japan] Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., Shigemoto K., Hitsumoto Y., Nikawa J.-I., Enomoto Y.; "Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes."; J. Biol. Chem. 276:44003-44011(2001).
[18]	STRUCTURE BY NMR OF 319-360. MEDLINE=94294808; PubMed=8023159; [NCBI, ExPASy, EBI, Israel, Japan] Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A.M.; "High-resolution structure of the oligomerization domain of p53 by multidimensional NMR."; Science 265:386-391(1994).
[19]	STRUCTURE BY NMR OF 325-355. MEDLINE=95292092; PubMed=7773777; [NCBI, ExPASy, EBI, Israel, Japan] Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; "Solution structure of the tetrameric minimum transforming domain of p53."; Nat. Struct. Biol. 1:877-890(1994).
[20]	STRUCTURE BY NMR OF 326-354. MEDLINE=98026899; PubMed=9321402; [NCBI, ExPASy, EBI, Israel, Japan] McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., Halazonetis T.D.; "Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain."; EMBO J. 16:6230-6236(1997).
[21]	X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. MEDLINE=94294806; PubMed=8023157; [NCBI, ExPASy, EBI, Israel, Japan] Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; "Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations."; Science 265:346-355(1994).
[22]	X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. MEDLINE=95184011; PubMed=7878469; [NCBI, ExPASy, EBI, Israel, Japan] Jeffrey P.D., Gorina S., Pavletich N.P.; "Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms."; Science 267:1498-1502(1995).
[23]	X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. MEDLINE=97081050; PubMed=8875929; [NCBI, ExPASy, EBI, Israel, Japan] Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P.; "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain."; Science 274:948-953(1996).
[24]	X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. MEDLINE=97035414; PubMed=8875926; [NCBI, ExPASy, EBI, Israel, Japan] Gorina S., Pavletich N.P.; "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2."; Science 274:1001-1005(1996).
[25]	REVIEW. MEDLINE=94090335; PubMed=8266092; [NCBI, ExPASy, EBI, Israel, Japan] Harris C.C.; "p53: at the crossroads of molecular carcinogenesis and risk assessment."; Science 262:1980-1981(1993).
[26]	REVIEW ON VARIANTS. MEDLINE=91289156; PubMed=1905840; [NCBI, ExPASy, EBI, Israel, Japan] Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; "p53 mutations in human cancers."; Science 253:49-53(1991).
[27]	REVIEW ON VARIANTS. MEDLINE=96271983; PubMed=8829653; [NCBI, ExPASy, EBI, Israel, Japan] de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., Liao D., Soussi T., Kovach J.S., Sommer S.S.; "Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses."; Hum. Mutat. 7:202-213(1996).
[28]	VARIANT ARG-72. MEDLINE=91153807; PubMed=1999338; [NCBI, ExPASy, EBI, Israel, Japan] Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; "Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population."; Hum. Genet. 86:369-370(1991).
[29]	VARIANT LFS THR-133. MEDLINE=92034774; PubMed=1933902; [NCBI, ExPASy, EBI, Israel, Japan] Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; "A germ line mutation in exon 5 of the p53 gene in an extended cancer family."; Cancer Res. 51:6385-6387(1991).
[30]	VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. MEDLINE=91057657; PubMed=1978757; [NCBI, ExPASy, EBI, Israel, Japan] Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms."; Science 250:1233-1238(1990).
[31]	VARIANT LFS ASP-245. MEDLINE=91080929; PubMed=2259385; [NCBI, ExPASy, EBI, Israel, Japan] Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; "Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome."; Nature 348:747-749(1990).
[32]	VARIANT LFS LEU-272. MEDLINE=92147883; PubMed=1737852; [NCBI, ExPASy, EBI, Israel, Japan] Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., Minna J.D.; "Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia."; J. Clin. Invest. 89:640-647(1992).
[33]	VARIANTS LFS HIS-273 AND VAL-325. MEDLINE=92228023; PubMed=1565144; [NCBI, ExPASy, EBI, Israel, Japan] Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; "Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms."; New Engl. J. Med. 326:1309-1315(1992).
[34]	VARIANTS BREAST TUMORS GLN-132; SER-249; LYS-280 AND LYS-285. MEDLINE=90295284; PubMed=1694291; [NCBI, ExPASy, EBI, Israel, Japan] Bartek J., Iggo R., Gannon J., Lane D.P.; "Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines."; Oncogene 5:893-899(1990).
[35]	VARIANTS COLON TUMORS PHE-241 AND HIS-273. MEDLINE=91017544; PubMed=1699228; [NCBI, ExPASy, EBI, Israel, Japan] Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., Gannon J.V., Lane D.P.; "p53 mutations in colorectal cancer."; Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
[36]	VARIANTS ESOPHAGUS TUMOR VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. MEDLINE=91088630; PubMed=2263646; [NCBI, ExPASy, EBI, Israel, Japan] Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; "Frequent mutation of the p53 gene in human esophageal cancer."; Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
[37]	VARIANTS COLORECTAL CANCER MUTATIONS. MEDLINE=91282784; PubMed=1647768; [NCBI, ExPASy, EBI, Israel, Japan] Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., Wakui A., Yamazaki T.; "Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors."; Biochem. Biophys. Res. Commun. 177:901-906(1991).
[38]	VARIANTS ESOPHAGUS TUMORS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. MEDLINE=91330175; PubMed=1868473; [NCBI, ExPASy, EBI, Israel, Japan] Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; "p53 gene mutations in Barrett's epithelium and esophageal cancer."; Cancer Res. 51:4495-4499(1991).
[39]	VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN CHINA. MEDLINE=91187113; PubMed=1849234; [NCBI, ExPASy, EBI, Israel, Japan] Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; Nature 350:427-428(1991).
[40]	VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN SOUTH AFRICA. MEDLINE=91187114; PubMed=1672732; [NCBI, ExPASy, EBI, Israel, Japan] Bressac B., Kew M., Wands J., Ozturk M.; "Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa."; Nature 350:429-431(1991).
[41]	VARIANTS HNSC PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. MEDLINE=93007999; PubMed=1394225; [NCBI, ExPASy, EBI, Israel, Japan] Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., Casey G.; "Frequent p53 mutations in head and neck cancer."; Cancer Res. 52:5997-6000(1992).
[42]	VARIANTS IN ANOGENITAL CARCINOMAS. MEDLINE=93010989; PubMed=1327751; [NCBI, ExPASy, EBI, Israel, Japan] Crook T., Vousden K.H.; "Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens."; EMBO J. 11:3935-3940(1992).
[43]	VARIANTS OSCC CYS-205; GLU-281 AND LYS-285. MEDLINE=93093790; PubMed=1459726; [NCBI, ExPASy, EBI, Israel, Japan] Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., Yamamoto H., Tsuchida N.; "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma."; Int. J. Cancer 52:867-872(1992).
[44]	VARIANT 177-PRO--HIS-178 DUPL. MEDLINE=93265016; PubMed=1303181; [NCBI, ExPASy, EBI, Israel, Japan] Bhatia K., Guiterrez M.I., Magrath I.T.; "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; Hum. Mol. Genet. 1:207-208(1992).
[45]	VARIANTS IN BURKITT'S LYMPHOMAS. MEDLINE=93064692; PubMed=1437144; [NCBI, ExPASy, EBI, Israel, Japan] Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., Appella E., May P.; "p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas."; Oncogene 7:2161-2167(1992).
[46]	VARIANT NASOPHARYNGEAL CARCINOMA THR-280. MEDLINE=92335329; PubMed=1631151; [NCBI, ExPASy, EBI, Israel, Japan] Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Cao Y., Yao K.-T., Colburn N.H.; "An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma."; Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
[47]	VARIANTS IN SCC OF THE HNSC. MEDLINE=93235942; PubMed=7682763; [NCBI, ExPASy, EBI, Israel, Japan] Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; "p53 alterations in human squamous cell carcinomas and carcinoma cell lines."; Am. J. Pathol. 142:1131-1139(1993).
[48]	VARIANTS IN HNSC. MEDLINE=94006220; PubMed=8402617; [NCBI, ExPASy, EBI, Israel, Japan] Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; "The incidence of p53 mutations increases with progression of head and neck cancer."; Cancer Res. 53:4477-4480(1993).
[49]	VARIANTS IN COLON TUMORS. MEDLINE=93330562; PubMed=8336944; [NCBI, ExPASy, EBI, Israel, Japan] Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; "Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors."; Oncogene 8:2213-2220(1993).
[50]	CHARACTERIZATION OF VARIANT ALA-143. MEDLINE=94283378; PubMed=8013454; [NCBI, ExPASy, EBI, Israel, Japan] Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; "A temperature-sensitive mutant of human p53."; EMBO J. 13:2535-2544(1994).
[51]	VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. MEDLINE=95193787; PubMed=7887414; [NCBI, ExPASy, EBI, Israel, Japan] Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., Fraumeni J.F. Jr., Li F.P., Friend S.H.; "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; Am. J. Hum. Genet. 56:608-615(1995).
[52]	VARIANT LFS HIS-175. MEDLINE=96423319; PubMed=8825920; [NCBI, ExPASy, EBI, Israel, Japan] Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53."; J. Med. Genet. 32:942-945(1995).
[53]	VARIANTS BA PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. MEDLINE=96233927; PubMed=8829627; [NCBI, ExPASy, EBI, Israel, Japan] Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; Hum. Mutat. 7:109-113(1996).
[54]	VARIANTS COLORECTAL TUMORS. MEDLINE=97255965; PubMed=9101296; [NCBI, ExPASy, EBI, Israel, Japan] Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., Zeuthen J.; "Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer."; Hum. Mutat. 9:348-355(1997).
[55]	VARIANT COLORECTAL CARCINOMA ILE-157. MEDLINE=98080146; PubMed=9419979; [NCBI, ExPASy, EBI, Israel, Japan] Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; "Drastic genetic instability of tumors and normal tissues in Turcot syndrome."; Oncogene 15:2877-2881(1997).
[56]	VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND SER-278. MEDLINE=98111377; PubMed=9450901; [NCBI, ExPASy, EBI, Israel, Japan] van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., Raubenheimer E.J.; "Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample."; Hum. Mutat. 11:39-44(1998).
[57]	VARIANT NONCLASSICAL LFS CYS-337. MEDLINE=98112421; PubMed=9452042; [NCBI, ExPASy, EBI, Israel, Japan] Luca J.W., Strong L.C., Hansen M.F.; "A germline missense mutation R337C in exon 10 of the human p53 gene."; Hum. Mutat. Suppl. 1:S58-S61(1998).

Comments

FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression.
SUBUNIT: Binds DNA as a homotetramer. In vitro, the interaction of TP53 with cancer-associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6.
SUBCELLULAR LOCATION: Nuclear.
ALTERNATIVE PRODUCTS: 2 isoforms; 1 (shown here) and 2/I9RET; are produced by alternative splicing. Isoform 2 seems to be non-functional is expressed in quiescent lymphocytes.
PTM: Phosphorylation on Ser residues mediates transcriptional activation.
PTM: Dephosphorylated by PP2A. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
PTM: O-linked glycosylation in the C-terminal basic region was studied in EB-1 cell line.
DISEASE: TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers.
DISEASE: Defects in TP53 are also the cause of germline cancers such as Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of both a proband with a sarcoma and two other first-degree relatives with a cancer by age 45 years. In these families the affected relatives develop a diverse set of malignancies including breast carcinomas, sarcomas, and brain tumors at unusually early ages.
DISEASE: Variant Ala-143 is temperature sensitive. At 32.5 degrees celsius it possesses strong DNA binding ability, but at 37.5 degrees celsius its transcriptional activities are greatly reduced.
DISEASE: Defects in TP53 are also the cause of Barrett's adenocarcinomas (BA). BA is a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
DISEASE: Defects in TP53 are the cause of head and neck squamous carcinomas (HNSC) and oral squamous cell carcinomas (OSCC). Cigarette smoke is a prime mutagenic agent in cancer of the aerodigestive tract.
SIMILARITY: BELONGS TO THE P53 FAMILY.
DATABASE: NAME=HotMolecBase; NOTE=p53 entry; WWW="http://bioinformatics.weizmann.ac.il/hotmolecbase/entries/p53.htm".
DATABASE: NAME=IARC p53; NOTE=IARC db of somatic p53 mutations; WWW="http://www.iarc.fr/p53/homepage.htm".
DATABASE: NAME=Tokyo p53; NOTE=University of Tokyo db of p53 mutations; WWW="http://p53.genome.ad.jp/".
DATABASE: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.; WWW="http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html".

Copyright

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).

Cross-references

EMBL

M14695; AAA61212.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22898; AAA59988.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22882; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22883; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22884; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22887; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22888; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22894; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22895; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22896; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M22897; AAA59988.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
K03199; AAA59989.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X01405; CAA25652.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M14694; AAA61211.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X02469; CAA26306.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
U94788; AAC12971.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
AF136271; AAD28628.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]
AF136270; AAD28628.1; JOINED.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X60012; CAA42627.1; ALT_TERM.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X54156; CAA38095.1; -.	[EMBL / GenBank / DDBJ] [CoDingSequence]

PIR

A25224; A25224.
A25397; A25397.
B25397; B25397.
JT0436; JT0436.

PDB

1OLG; 08-MAR-95.	[ExPASy / RCSB]
1OLH; 31-MAR-95.	[ExPASy / RCSB]
1SAE; 15-OCT-95.	[ExPASy / RCSB]
1SAF; 15-OCT-95.	[ExPASy / RCSB]
1SAG; 15-OCT-95.	[ExPASy / RCSB]
1SAH; 15-OCT-95.	[ExPASy / RCSB]
1SAI; 15-OCT-95.	[ExPASy / RCSB]
1SAJ; 15-OCT-95.	[ExPASy / RCSB]
1SAK; 15-OCT-95.	[ExPASy / RCSB]
1SAL; 15-OCT-95.	[ExPASy / RCSB]
1TSR; 29-JAN-96.	[ExPASy / RCSB]
1AIE; 16-JUN-97.	[ExPASy / RCSB]
1PES; 07-FEB-95.	[ExPASy / RCSB]
1PET; 07-FEB-95.	[ExPASy / RCSB]
1TUP; 07-DEC-95.	[ExPASy / RCSB]
1YCQ; 19-NOV-97.	[ExPASy / RCSB]
1YCR; 19-NOV-97.	[ExPASy / RCSB]
1YCS; 19-NOV-97.	[ExPASy / RCSB]
1A1U; 08-APR-98.	[ExPASy / RCSB]
1C26; 24-JAN-01.	[ExPASy / RCSB]

Detailed list of linked structures.

T00671; -.

P04637; HUMAN.

HGNC:11998; TP53.

HGNC:11998; TP53.

191170 [NCBI / EBI].
151623 [NCBI / EBI].

TP53; Homo sapiens.

TP53; Homo sapiens.

P04637; Homo sapiens. [Entry / Contig view]

InterPro

IPR002117; P53.
Graphical view of domain structure.

Pfam

PF00870; P53; 1.

PRINTS

PR00386; P53SUPPRESSR.

ProDom

PD002681; P53; 1.
[Domain structure / List of seq. sharing at least 1 domain].

PS00348; P53; 1.

Keywords

Anti-oncogene; DNA-binding; Transcription regulation; Activator; Nuclear protein; Phosphorylation; Glycoprotein; Apoptosis; Alternative splicing; Disease mutation; Polymorphism; 3D-structure; Li-Fraumeni syndrome.

Features

`Key`	`From To`	`Length`	`Description`
`DOMAIN`	`1 44`	`44`	`TRANSCRIPTION ACTIVATION (ACIDIC).`
`DNA_BIND`	`102 292`	`191`
`DOMAIN`	`325 356`	`32`	`OLIGOMERIZATION.`
`DOMAIN`	`368 387`	`20`	`BASIC (REPRESSION OF DNA-BINDING).`
`DOMAIN`	`241 248`	`8`	`INTERACTS WITH THE 53BP2 SH3 DOMAIN.`
`DOMAIN`	`311 323`	`13`	`NUCLEAR LOCALIZATION SIGNAL.`
`DOMAIN`	`339 346`	`8`	`TRANSCRIPTIONAL REPRESSION.`
`MOD_RES`	`15 15`		`PHOSPHORYLATION (BY PRPK).`
`MOD_RES`	`315 315`		`PHOSPHORYLATION (BY CDC2).`
`MOD_RES`	`392 392`		`PHOSPHORYLATION (BY SIMILARITY).`
`VARSPLIC`	`332 341`		`IRGRERFEMF -> DGTSFQKENC (IN ISOFORM 2).`
`VARSPLIC`	`342 393`		`MISSING (IN ISOFORM 2).`
`VARIANT`	`7 7`		`D -> H (IN A SKIN TUMOR). /FTId=VAR_005851.`
`VARIANT`	`35 35`		`L -> F (IN A LIVER TUMOR). /FTId=VAR_005852.`
`VARIANT`	`43 43`		`L -> S (IN A RENAL TUMOR). /FTId=VAR_005853.`
`VARIANT`	`47 47`		`P -> S (IN DBSNP:1800371) [NCBI/Ensembl]. /FTId=VAR_014632.`
`VARIANT`	`53 53`		`W -> C (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005854.`
`VARIANT`	`60 60`		`P -> S (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005855.`
`VARIANT`	`72 72`		`P -> R (IN DBSNP:1042522) [NCBI/Ensembl]. /FTId=VAR_005856.`
`VARIANT`	`79 79`		`A -> T (IN CLONE P53-H-1). /FTId=VAR_005857.`
`VARIANT`	`87 87`		`P -> Q (IN A BRAIN TUMOR). /FTId=VAR_005858.`
`VARIANT`	`94 94`		`S -> T (IN A COLON TUMOR). /FTId=VAR_005859.`
`VARIANT`	`110 110`		`R -> C (IN A LIVER AND AN UTERUS TUMOR). /FTId=VAR_005860.`
`VARIANT`	`110 110`		`R -> L (IN A LIVER TUMOR). /FTId=VAR_005861.`
`VARIANT`	`110 110`		`R -> P (IN A BREAST TUMOR). /FTId=VAR_005862.`
`VARIANT`	`113 113`		`F -> C (IN A LUNG TUMOR). /FTId=VAR_005863.`
`VARIANT`	`125 125`		`T -> M (IN A LUNG TUMOR). /FTId=VAR_005864.`
`VARIANT`	`126 126`		`Y -> D (IN A COLORECTAL TUMOR). /FTId=VAR_005865.`
`VARIANT`	`126 126`		`Y -> N (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005866.`
`VARIANT`	`127 127`		`S -> F (IN A LUNG TUMOR). /FTId=VAR_005867.`
`VARIANT`	`128 128`		`P -> S (IN A BREAST TUMOR). /FTId=VAR_005868.`
`VARIANT`	`129 129`		`A -> D (IN A SARCOMA). /FTId=VAR_005869.`
`VARIANT`	`130 130`		`L -> R (IN A LIVER TUMOR). /FTId=VAR_005870.`
`VARIANT`	`131 131`		`N -> S (IN A LIVER TUMOR). /FTId=VAR_005871.`
`VARIANT`	`131 131`		`N -> K (IN A COLON TUMOR). /FTId=VAR_005872.`
`VARIANT`	`132 132`		`K -> M (IN A SARCOMA). /FTId=VAR_005873.`
`VARIANT`	`132 132`		`K -> Q (IN A BREAST TUMOR). /FTId=VAR_005874.`
`VARIANT`	`133 133`		`M -> T (IN LFS). /FTId=VAR_005875.`
`VARIANT`	`135 135`		`C -> S (IN A COLON TUMOR). /FTId=VAR_005876.`
`VARIANT`	`135 135`		`C -> F (IN A COLON TUMOR). /FTId=VAR_005877.`
`VARIANT`	`136 136`		`Q -> E (IN A BREAST TUMOR). /FTId=VAR_005878.`
`VARIANT`	`136 136`		`Q -> K (IN A COLON TUMOR). /FTId=VAR_005879.`
`VARIANT`	`137 137`		`L -> Q (IN A LIVER TUMOR). /FTId=VAR_005880.`
`VARIANT`	`138 138`		`A -> P (IN A LUNG TUMOR). /FTId=VAR_005881.`
`VARIANT`	`139 139`		`K -> N (IN A BREAST, AN OVARY TUMOR, A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005882.`
`VARIANT`	`140 140`		`T -> Y (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005883.`
`VARIANT`	`141 141`		`C -> G (IN AN OVARY TUMOR). /FTId=VAR_005884.`
`VARIANT`	`141 141`		`C -> F (IN A BREAST TUMOR). /FTId=VAR_005885.`
`VARIANT`	`141 141`		`C -> Y (IN MANY TYPES OF TUMORS). /FTId=VAR_005886.`
`VARIANT`	`143 143`		`V -> A (IN A COLON TUMOR). /FTId=VAR_005887.`
`VARIANT`	`144 144`		`Q -> P (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005888.`
`VARIANT`	`145 145`		`L -> P (IN A BRAIN TUMOR). /FTId=VAR_005889.`
`VARIANT`	`145 145`		`L -> Q (IN AN ESOPHAGUS TUMOR). /FTId=VAR_005890.`
`VARIANT`	`147 147`		`V -> D (IN AN OVARY TUMOR). /FTId=VAR_005891.`
`VARIANT`	`147 147`		`V -> G (IN A PROSTATE TUMOR). /FTId=VAR_005892.`
`VARIANT`	`149 149`		`S -> P (IN A BREAST TUMOR). /FTId=VAR_005893.`
`VARIANT`	`151 151`		`P -> A (IN A BRAIN AND A COLON TUMOR). /FTId=VAR_005894.`
`VARIANT`	`151 151`		`P -> S (IN MANY TYPES OF TUMORS). /FTId=VAR_005895.`
`VARIANT`	`151 151`		`P -> T (IN A BREAST TUMOR). /FTId=VAR_005896.`
`VARIANT`	`152 152`		`P -> L (IN AN ESOPHAGUS TUMOR). /FTId=VAR_005897.`
`VARIANT`	`152 152`		`P -> S (IN OSCC). /FTId=VAR_005898.`
`VARIANT`	`153 153`		`P -> T (IN A COLON TUMOR). /FTId=VAR_005899.`
`VARIANT`	`154 154`		`G -> V (IN ESOPHAGUS TUMOR). /FTId=VAR_005900.`
`VARIANT`	`155 155`		`T -> A (IN AN ESOPHAGUS TUMOR). /FTId=VAR_005901.`
`VARIANT`	`156 156`		`R -> P (IN AN OSTEOSARCOMA CELL LINE). /FTId=VAR_005902.`
`VARIANT`	`157 157`		`V -> D (IN A LIVER TUMOR). /FTId=VAR_005903.`
`VARIANT`	`157 157`		`V -> I (IN COLORECTAL CARCINOMA FROM A PATIENT WITH TURCOT SYNDROME). /FTId=VAR_012977.`
`VARIANT`	`157 157`		`V -> S (IN A S.AFRICAN HEPATOCELLULAR CARCINOMA). /FTId=VAR_005904.`
`VARIANT`	`158 158`		`R -> C (IN A NONINVASIVE HEAD AND NECK TUMOR). /FTId=VAR_005905.`
`VARIANT`	`158 158`		`R -> G (IN A BRAIN AND A LUNG TUMOR). /FTId=VAR_005906.`
`VARIANT`	`158 158`		`R -> H (IN A MANY TYPES OF TUMORS). /FTId=VAR_005907.`
`VARIANT`	`160 160`		`M -> I (IN A LUNG AND A SKIN TUMOR). /FTId=VAR_005908.`
`VARIANT`	`161 161`		`A -> S (IN A BRAIN TUMOR). /FTId=VAR_005909.`
`VARIANT`	`162 162`		`I -> S (IN A BRAIN TUMOR). /FTId=VAR_005910.`
`VARIANT`	`162 162`		`I -> V (IN AN OVARY TUMOR). /FTId=VAR_005911.`
`VARIANT`	`163 163`		`Y -> H (IN HNSC). /FTId=VAR_005912.`
`VARIANT`	`164 164`		`K -> N (IN A LUNG TUMOR). /FTId=VAR_005913.`
`VARIANT`	`164 164`		`K -> Q (IN A BREAST TUMOR). /FTId=VAR_005914.`
`VARIANT`	`165 165`		`Q -> L (IN A BREAST TUMOR). /FTId=VAR_005915.`
`VARIANT`	`165 165`		`Q -> R (IN AN OVARY TUMOR). /FTId=VAR_005916.`
`VARIANT`	`166 166`		`S -> L (IN A LUNG TUMOR). /FTId=VAR_005917.`
`VARIANT`	`168 168`		`H -> R (IN A BRAIN TUMOR). /FTId=VAR_005918.`
`VARIANT`	`169 169`		`M -> I (IN OSCC). /FTId=VAR_005919.`
`VARIANT`	`169 169`		`M -> T (IN A NONINVASIVE HEAD AND NECK TUMOR). /FTId=VAR_005920.`
`VARIANT`	`170 170`		`T -> M (IN A COLON TUMOR). /FTId=VAR_005921.`
`VARIANT`	`170 170`		`T -> S (IN A COLON TUMOR). /FTId=VAR_005922.`
`VARIANT`	`172 172`		`V -> A (IN A PROSTATE TUMOR). /FTId=VAR_005923.`
`VARIANT`	`173 173`		`V -> E (IN A COLON TUMOR). /FTId=VAR_005924.`
`VARIANT`	`173 173`		`V -> L (IN A CERVICAL CARCINOMA). /FTId=VAR_005925.`
`VARIANT`	`173 173`		`V -> M (IN A COLON TUMOR). /FTId=VAR_005926.`
`VARIANT`	`174 174`		`R -> H (IN THE CELL LINE DETROIT 562 OF SQUAMOUS CELL CARCINOMA). /FTId=VAR_005927.`
`VARIANT`	`175 175`		`R -> C (IN A COLON AND AN UTERUS TUMOR). /FTId=VAR_005928.`
`VARIANT`	`175 175`		`R -> G (IN A BRAIN TUMOR). /FTId=VAR_005929.`
`VARIANT`	`175 175`		`R -> L (IN A BREAST AND A COLON TUMOR). /FTId=VAR_005930.`
`VARIANT`	`175 175`		`R -> P (IN A CERVICAL CARCINOMA). /FTId=VAR_005931.`
`VARIANT`	`175 175`		`R -> H (IN LFS, COLON/ESOPHAGUS/GASTRIC TUMORS). /FTId=VAR_005932.`
`VARIANT`	`176 176`		`C -> F (IN BA AND MANY TYPES OF TUMORS). /FTId=VAR_005933.`
`VARIANT`	`176 176`		`C -> W (IN A LUNG TUMOR). /FTId=VAR_005934.`
`VARIANT`	`177 177`		`P -> L (IN A SKIN TUMOR). /FTId=VAR_005935.`
`VARIANT`	`178 178`		`H -> HPHP (IN A BURKITT'S LYMPHOMA). /FTId=VAR_005936.`
`VARIANT`	`181 181`		`R -> L (IN A CERVICAL CARCINOMA). /FTId=VAR_005937.`
`VARIANT`	`182 182`		`C -> S (IN A STOMACH TUMOR). /FTId=VAR_005938.`
`VARIANT`	`184 184`		`D -> Y (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005939.`
`VARIANT`	`186 186`		`D -> Y (IN A BREAST TUMOR). /FTId=VAR_005940.`
`VARIANT`	`187 187`		`G -> C (IN A BREAST TUMOR). /FTId=VAR_005941.`
`VARIANT`	`187 187`		`G -> S (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005942.`
`VARIANT`	`189 189`		`A -> P (IN AN OVARY TUMOR). /FTId=VAR_005943.`
`VARIANT`	`190 190`		`P -> L (IN A COLORECTAL TUMOR). /FTId=VAR_005944.`
`VARIANT`	`191 191`		`P -> T (IN A COLON TUMOR). /FTId=VAR_005945.`
`VARIANT`	`192 192`		`Q -> R (IN A COLON TUMOR). /FTId=VAR_005946.`
`VARIANT`	`193 193`		`H -> D (IN AN UTERUS TUMOR). /FTId=VAR_005947.`
`VARIANT`	`193 193`		`H -> R (IN LFS). /FTId=VAR_005948.`
`VARIANT`	`194 194`		`L -> P (IN A COLON TUMOR). /FTId=VAR_005949.`
`VARIANT`	`194 194`		`L -> R (IN THE CELL LINE HU 281 OF SQUAMOUS CELL CARCINOMA). /FTId=VAR_005950.`
`VARIANT`	`195 195`		`I -> T (IN OSCC). /FTId=VAR_005951.`
`VARIANT`	`198 198`		`E -> K (IN HNSC). /FTId=VAR_005952.`
`VARIANT`	`205 205`		`Y -> C (IN OSCC). /FTId=VAR_005953.`
`VARIANT`	`205 205`		`Y -> D (IN HNSC). /FTId=VAR_005954.`
`VARIANT`	`213 213`		`R -> Q (IN A BURKITT'S LYMPHOMA AND A COLORECTAL TUMOR). /FTId=VAR_005955.`
`VARIANT`	`216 216`		`V -> M (IN HNSC). /FTId=VAR_005956.`
`VARIANT`	`220 220`		`Y -> C (IN OSCC). /FTId=VAR_005957.`
`VARIANT`	`220 220`		`Y -> H (IN A COLON TUMOR). /FTId=VAR_005958.`
`VARIANT`	`220 220`		`Y -> S (IN HNSC). /FTId=VAR_005959.`
`VARIANT`	`228 228`		`D -> E (IN HNSC). /FTId=VAR_005960.`
`VARIANT`	`230 230`		`T -> I (IN OSCC). /FTId=VAR_005961.`
`VARIANT`	`232 232`		`I -> T (IN AN ANAL TUMOR). /FTId=VAR_005962.`
`VARIANT`	`234 234`		`Y -> C (IN HNSC). /FTId=VAR_005963.`
`VARIANT`	`234 234`		`Y -> H (IN A BURKITT'S LYMPHOMA). /FTId=VAR_005964.`
`VARIANT`	`237 237`		`M -> I (IN A COLON TUMOR). /FTId=VAR_005965.`
`VARIANT`	`238 238`		`C -> F (IN AN ANAL TUMOR). /FTId=VAR_005966.`
`VARIANT`	`238 238`		`C -> Y (IN A COLORECTAL TUMOR). /FTId=VAR_005967.`
`VARIANT`	`240 240`		`S -> I (IN AN ANAL TUMOR). /FTId=VAR_005968.`
`VARIANT`	`241 241`		`S -> F (IN A COLON TUMOR). /FTId=VAR_005969.`
`VARIANT`	`242 242`		`C -> F (IN A SKIN TUMOR). /FTId=VAR_005970.`
`VARIANT`	`245 245`		`G -> A (IN A RENAL TUMOR). /FTId=VAR_005971.`
`VARIANT`	`245 245`		`G -> C (IN LFS; IN OSTEOSARCOMA; COLON AND LARYNX TUMORS). /FTId=VAR_005972.`
`VARIANT`	`245 245`		`G -> D (IN LFS AND IN A COLON TUMOR). /FTId=VAR_005973.`
`VARIANT`	`245 245`		`G -> S (IN BA AND MANY TYPES OF TUMORS). /FTId=VAR_005974.`
`VARIANT`	`245 245`		`G -> V (IN HNSC). /FTId=VAR_005975.`
`VARIANT`	`246 246`		`M -> R (IN A LIVER TUMOR). /FTId=VAR_005976.`
`VARIANT`	`246 246`		`M -> T (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_005977.`
`VARIANT`	`246 246`		`M -> V (IN A MANY TYPES OF TUMORS). /FTId=VAR_005978.`
`VARIANT`	`247 247`		`N -> W (IN A SKIN TUMOR). /FTId=VAR_005979.`
`VARIANT`	`247 247`		`N -> I (IN A LUNG TUMOR). /FTId=VAR_005980.`
`VARIANT`	`248 248`		`R -> G (IN AN ENDOCRINE TUMOR). /FTId=VAR_005981.`
`VARIANT`	`248 248`		`R -> L (IN HYPOPHARYNX; LARYNX AND TONSIL TUMORS). /FTId=VAR_005982.`
`VARIANT`	`248 248`		`R -> Q (IN LFS AND IN MANY TYPES OF TUMORS). /FTId=VAR_005983.`
`VARIANT`	`248 248`		`R -> W (IN LFS, BA AND IN MANY TYPES OF TUMORS). /FTId=VAR_005984.`
`VARIANT`	`249 249`		`R -> G (IN A BREAST TUMOR). /FTId=VAR_005985.`
`VARIANT`	`249 249`		`R -> S (IN MANY TYPES OF TUMORS). /FTId=VAR_005986.`
`VARIANT`	`251 251`		`I -> N (IN HNSC). /FTId=VAR_005987.`
`VARIANT`	`252 252`		`L -> P (IN LFS AND IN MANY TYPES OF TUMORS). /FTId=VAR_005988.`
`VARIANT`	`257 257`		`L -> P (IN HNSC). /FTId=VAR_005989.`
`VARIANT`	`258 258`		`E -> D (IN A COLORECTAL TUMOR). /FTId=VAR_005990.`
`VARIANT`	`258 258`		`E -> K (IN LFS AND IN BREAST CANCER CELLS). /FTId=VAR_005991.`
`VARIANT`	`272 272`		`V -> L (IN LFS). /FTId=VAR_005992.`
`VARIANT`	`273 273`		`R -> C (IN LFS; IN COLORECTAL TUMOR AND OSCC). /FTId=VAR_005993.`
`VARIANT`	`273 273`		`R -> G (IN HNSC). /FTId=VAR_005994.`
`VARIANT`	`273 273`		`R -> H (IN LFS, COLON AND ESOPHAGUS TUMORS). /FTId=VAR_005995.`
`VARIANT`	`274 274`		`V -> F (IN A COLORECTAL TUMOR). /FTId=VAR_005997.`
`VARIANT`	`275 275`		`C -> Y (IN LFS, A BRAIN, A LUNG, A RENAL, A STOMACH TUMOR). /FTId=VAR_005998.`
`VARIANT`	`275 275`		`C -> W (IN A BREAST AND A STOMACH TUMOR). /FTId=VAR_005999.`
`VARIANT`	`277 277`		`C -> G (IN A LUNG TUMOR). /FTId=VAR_006000.`
`VARIANT`	`278 278`		`P -> A (IN A BREAST TUMOR). /FTId=VAR_006001.`
`VARIANT`	`278 278`		`P -> H (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_006002.`
`VARIANT`	`278 278`		`P -> L (IN AN ESOPHAGUS AND A LUNG TUMOR). /FTId=VAR_006003.`
`VARIANT`	`278 278`		`P -> S (IN OSCC). /FTId=VAR_006004.`
`VARIANT`	`278 278`		`P -> T (IN HNSC; SAME PATIENT AS MUTATION HIS-281). /FTId=VAR_006005.`
`VARIANT`	`279 279`		`G -> E (IN A COLORECTAL TUMOR). /FTId=VAR_006006.`
`VARIANT`	`280 280`		`R -> K (IN A BREAST TUMOR). /FTId=VAR_006007.`
`VARIANT`	`280 280`		`R -> I (IN A COLORECTAL TUMOR). /FTId=VAR_006008.`
`VARIANT`	`280 280`		`R -> T (IN NASOPHARYNGEAL CARCINOMA). /FTId=VAR_006009.`
`VARIANT`	`281 281`		`D -> A (IN A LEUKEMIA AND A LYMPHOMA). /FTId=VAR_006010.`
`VARIANT`	`281 281`		`D -> E (IN MANY TYPES OF TUMORS). /FTId=VAR_006011.`
`VARIANT`	`281 281`		`D -> G (IN MANY TYPES OF TUMORS). /FTId=VAR_006012.`
`VARIANT`	`281 281`		`D -> H (IN HNSC; SAME PATIENT AS MUTATION THR-278). /FTId=VAR_006013.`
`VARIANT`	`281 281`		`D -> V (IN A COLORECTAL TUMOR). /FTId=VAR_006014.`
`VARIANT`	`282 282`		`R -> L (IN A BREAST TUMOR). /FTId=VAR_006015.`
`VARIANT`	`282 282`		`R -> W (IN BA AND MANY TYPES OF TUMORS). /FTId=VAR_006016.`
`VARIANT`	`283 283`		`R -> C (IN A COLON TUMOR). /FTId=VAR_006017.`
`VARIANT`	`283 283`		`R -> G (IN A LUNG TUMOR). /FTId=VAR_006018.`
`VARIANT`	`283 283`		`R -> H (IN A COLON TUMOR). /FTId=VAR_006019.`
`VARIANT`	`283 283`		`R -> P (IN A BREAST AND A LUNG TUMOR). /FTId=VAR_006020.`
`VARIANT`	`284 284`		`T -> A (IN A COLORECTAL TUMOR). /FTId=VAR_006021.`
`VARIANT`	`284 284`		`T -> P (IN A LUNG TUMOR). /FTId=VAR_006022.`
`VARIANT`	`285 285`		`E -> K (IN MANY TYPES OF TUMORS). /FTId=VAR_006023.`
`VARIANT`	`285 285`		`E -> Q (IN AN UTERUS TUMOR). /FTId=VAR_006024.`
`VARIANT`	`285 285`		`E -> V (IN A LIVER TUMOR). /FTId=VAR_006025.`
`VARIANT`	`286 286`		`E -> A (IN LFS). /FTId=VAR_006026.`
`VARIANT`	`286 286`		`E -> D (IN A LIVER TUMOR). /FTId=VAR_006027.`
`VARIANT`	`286 286`		`E -> G (IN A COLON, A LUNG, A HEAD AND A NECK TUMOR). /FTId=VAR_006028.`
`VARIANT`	`286 286`		`E -> K (IN MANY TYPES OF TUMORS). /FTId=VAR_006029.`
`VARIANT`	`286 286`		`E -> Q (IN BA). /FTId=VAR_006030.`
`VARIANT`	`296 296`		`H -> P (IN HNSC). /FTId=VAR_006031.`
`VARIANT`	`300 300`		`P -> R (IN A SKIN TUMOR). /FTId=VAR_006032.`
`VARIANT`	`301 301`		`P -> L (IN A COLON TUMOR). /FTId=VAR_006033.`
`VARIANT`	`302 302`		`G -> E (IN A COLON TUMOR). /FTId=VAR_006034.`
`VARIANT`	`302 302`		`G -> V (IN A COLON TUMOR). /FTId=VAR_006035.`
`VARIANT`	`306 306`		`R -> Q (IN A SARCOMA). /FTId=VAR_006036.`
`VARIANT`	`307 307`		`A -> T (IN A BREAST TUMOR). /FTId=VAR_006037.`
`VARIANT`	`309 309`		`P -> S (IN A COLON TUMOR). /FTId=VAR_006038.`
`VARIANT`	`325 325`		`G -> V (IN LFS). /FTId=VAR_006039.`
`VARIANT`	`334 334`		`G -> V (IN A LUNG TUMOR). /FTId=VAR_006040.`
`VARIANT`	`337 337`		`R -> C (IN A LIVER TUMOR AND NONCLASSICAL LFS). /FTId=VAR_006041.`
`MUTAGEN`	`135 135`		`C->Y: DECREASED E6-MEDIATED BINDING TO E6-AP.`
`STRAND`	`103 103`	`1`
`HELIX`	`105 107`	`3`
`TURN`	`108 108`	`1`
`STRAND`	`110 112`	`3`
`TURN`	`120 121`	`2`
`STRAND`	`124 127`	`4`
`TURN`	`128 131`	`4`
`STRAND`	`132 135`	`4`
`TURN`	`137 138`	`2`
`STRAND`	`141 146`	`6`
`TURN`	`153 154`	`2`
`STRAND`	`156 163`	`8`
`TURN`	`166 170`	`5`
`HELIX`	`177 181`	`5`
`TURN`	`191 192`	`2`
`STRAND`	`195 197`	`3`
`TURN`	`201 202`	`2`
`STRAND`	`204 207`	`4`
`TURN`	`209 211`	`3`
`STRAND`	`214 219`	`6`
`TURN`	`225 226`	`2`
`STRAND`	`230 236`	`7`
`TURN`	`240 241`	`2`
`TURN`	`243 248`	`6`
`STRAND`	`251 258`	`8`
`TURN`	`260 261`	`2`
`STRAND`	`264 274`	`11`
`HELIX`	`278 286`	`9`
`HELIX`	`335 354`	`20`

	Feature aligner
	Feature table viewer

Sequence information

Length: 393 AA

Molecular weight: 43653 Da

CRC64: AD5C149FD8106131 [This is a checksum on the sequence]

        10         20         30         40         50         60 
         |          |          |          |          |          | 
MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP 

        70         80         90        100        110        120 
         |          |          |          |          |          | 
DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK 

       130        140        150        160        170        180 
         |          |          |          |          |          | 
SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE 

       190        200        210        220        230        240 
         |          |          |          |          |          | 
RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS 

       250        260        270        280        290        300 
         |          |          |          |          |          | 
SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP 

       310        320        330        340        350        360 
         |          |          |          |          |          | 
PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG 

       370        380        390 
         |          |          | 
GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD

P04637 in FASTA format

View entry in original Swiss-Prot format
View entry in raw text format (no links)
Report form for errors/updates in this Swiss-Prot entry

	BLAST submission on ExPASy/SIB or at NCBI (USA)		Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
	ScanProsite, MotifScan		Search the SWISS-MODEL Repository

ExPASy Home page

Site Map

Search ExPASy

Contact us

Swiss-Prot

Mirror sites: